AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Cancer Biology & Medicine Article
PDF (3.9 MB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Letter | Open Access

Non-essential role of S100A9 in hematopoiesis in primary MPN and MDS mouse models

Qinglin Li1,*, Xuezhen Ma1,*, Zhaofeng Li1,*, Xinshu Xie1, Yating Lu1, Hanqi Liu1, Ailing Zou1, Yexin Yang1, Jie Ouyang1, Shuqian Xu2 ( ), Yang Mei1 ( )
School of Biomedical Sciences, Hunan Provincial Key Laboratory of Animal Model and Molecular Medicine, Hunan University, Changsha 410082, China
Department of Hematology, Qilu Hospital of Shandong University, Jinan 250012, China

*These authors contributed equally to this work.

Show Author Information

Electronic Supplementary Material

Download File(s)
cbm-22-7-806_ESM.pdf (2 MB)

References

【1】
【1】
 
 
Crossref Google Scholar
Cancer Biology & Medicine
Volume 22 Issue 7,
July 2025
Pages 806-811
DOI: 10.20892/j.issn.2095-3941.2025.0185

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Cite this Report
Close
Close
Cite this article:
Li Q, Ma X, Li Z, et al. Non-essential role of S100A9 in hematopoiesis in primary MPN and MDS mouse models. Cancer Biology & Medicine, 2025, 22(7): 806-811. https://doi.org/10.20892/j.issn.2095-3941.2025.0185

433

Views

37

Downloads

0

Crossref

0

Web of Science

0

Scopus
Received: 13 April 2025
Accepted: 03 June 2025
Published: 26 July 2025
©2025 The Authors.

Creative Commons Attribution-NonCommercial 4.0 International License